Research & Development: Page 73
-
PharmaVoice Team/PharmaVoice
Index
Julian Adams, Ph.D. President, Research and Development and Chief Scientific Officer, Infinity Pharmaceuticals Inc. Brent Ahrens. General Partner, Canaan Partners Kenneth C. Aldrich. CEO, Chairman, and Co-Founder, International Stem Cell Corp. Meryl Allison. Principal, Deloitte Consulting Karl...
By PharmaVoice Team • Nov. 9, 2009 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Service Consolidation Recommended for Clinical trial Offices Emerging centralized clinical trial offices (CTOs) are among the newest developments within the research administration infrastructure of academic health centers. Little uniformity exists in the structure or functions of existing CTOs, ...
By PharmaVoice Team • Nov. 9, 2009 -
Explore the Trendline➔
Stock via Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
What's New
inVentiv Health’s recently launched risk evaluation and mitigation strategy (REMS) offering provides pharmaceutical and biotechnology clients with a customizable suite of REMS-related services that can be delivered through a single, integrated program. In an effort to assure safe use of prescript...
By PharmaVoice Team • Nov. 9, 2009 -
PharmaVoice Team/PharmaVoice
PharmaTrax
buster brands,”says David Lipson,forecasting practice leader at IMS Global Consulting.“But we are not see ing the avalanche that some feared. Although the number of major new product launches was smaller than usual last year, the genuine value provided by medicines introduced over the past dozen ...
By PharmaVoice Team • Nov. 3, 2009 -
PharmaVoice Team/PharmaVoice
The End of the Paper Chase
Responses to an ongoing survey and face to face discussions with executives from pharmaceutical and biotech companies reveal their greatest concerns and hopes as they begin to streamline the clinicaltrials process. IN AN EXCLUSIVE WITH PHARMAVOICE, ELLEN SEMPLE,VP, MARKETING, CB TECHNOLOGIES INC....
By PharmaVoice Team • Nov. 2, 2009 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharma POOL Robert GELBARD ICN Pharmaceuticals Appoints Former Ambassador to Head International Efforts Former Ambassador Robert Gelbard joins ICN Pharmaceuticals Inc. as senior VP for international affairs and government relations. Mr. Gelbard is the com pany representative with foreign governme...
By PharmaVoice Team • Nov. 2, 2009 -
PharmaVoice Team/PharmaVoice
E-Media
NEW ELECTRONIC AND WEBBASED APPLICATIONS, SITES, AND TECHNOLOGIES BioSpace Inc., a provider of Webbased products and information services to the life sciences industry, has formed a collaboration with MediBic, a Japanese bioventure company, to exchange information in an effort to support new biot...
By PharmaVoice Team • Nov. 2, 2009 -
PharmaVoice Team/PharmaVoice
What's New
WHAT’S NEW NEW HEALTHCARERELATED PRODUCTS, SERVICES, AND COMPANIES Noonan Russo Communications has agreed to merge its operations with the public relations division of Euro RSCG Healthview, establishing a new company — Noonan Russo Presence Euro RSCG. The new entity, a differentiated communicatio...
By PharmaVoice Team • Oct. 30, 2009 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Extending its line of therapeutic class research, NOP World Health has added Diabetes Patient Market Study to its portfolio of disease state research. The staff of diabetes experts who support the study, which has been produced by NOP World Health’s sister com pany, RoperASW since 1989, will be i...
By PharmaVoice Team • Oct. 30, 2009 -
PharmaVoice Team/PharmaVoice
Pharma Outlet
The pharmaceutical industry is facing a crucial short age in the area of clinical trials. With an estimated 4,360 new drugs in the pipeline, it has become an increasing challenge for the industry to recruit both qualified patient volunteers and experienced researchers. Only an estimated 5 million...
By Kathleen H. Drennan • Oct. 29, 2009 -
PharmaVoice Team/PharmaVoice
Brave New Digital World
Pharma companies must be bold and confident in their deployment of electronic solutions or risk being left behind on the technological superhighway. Patients and physicians are migrating in droves toward Web- and mobile-based healthcare solutions. The overall number of e-health consumers who go o...
By PharmaVoice Team • Oct. 27, 2009 -
PharmaVoice Team/PharmaVoice
What's Missing in eSolutions: Enabling the Redefinition of Clinical Development
There’s something missing from the eSolutions discussion. In fact, there are two key missing links: n eSolutions that are no more than bridges between silos will not meet the needs of a rapidly changing clinical development environment; and n Strategies, pilots, and initial use of eSolutions are ...
By PharmaVoice Team • Oct. 27, 2009 -
PharmaVoice Team/PharmaVoice
eClinical Feedback: Why Sponsors Need an Integrated, Closed-Loop Clinical Process
David Gemzik, Vice President, Implementation Services Sean Cheng, Senior Product Marketing Manager Faced with slowing pipe lines and spiraling costs in new drug development, sponsors in recent years have been trying to conquer the last frontier in process improvement: R&D. However, increasing...
By PharmaVoice Team • Oct. 27, 2009 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
3 PUBLISHER Lisa Banket EDITOR Taren Grom CREATIVE DIRECTOR Marah Walsh DIRECTOR OF SALES Darlene Kwiatkowski CONTRIBUTING EDITORS Virginia Kirk Denise Myshko Elisabeth Pena Kim Ribbink Deborah Ruriani Lynda Sears Copyright 2002 by PharmaLinx LLC, Titusville, NJ Printed in the U.S.A. Volume Two, ...
By Taren Grom • Oct. 23, 2009 -
PharmaVoice Team/PharmaVoice
The Nose Knows
Many of the properties that make the nose an effective way for an illicit drug user to get a “fix” are actually qualities that doctors and patients are seeking for legitimate treatments — a noninjection form that delivers medication in highly targeted, quickly absorbed doses. Britannia Pharmaceut...
By Taren Grom • Oct. 23, 2009 -
PharmaVoice Team/PharmaVoice
PharmaTrax
$7 Billion in revenue predicted for ADVANCED DRUG DELIVERY SYSTEMS by 2005 The market for drugs employing advanced drug delivery technologies will surpass $7 billion by 2005,according to a study from Kalorama Information.The market segment has seen doubledigit growth over the past few years, and ...
By PharmaVoice Team • Oct. 23, 2009 -
PharmaVoice Team/PharmaVoice
Pharma Outlet
Despite a history of new product launches, strong growth, and increased research spending, it is clear that the pharmaceutical industry is in a period of major transition. The challenge facing the industry is one of creating a sustainable pipeline that can generate the longterm growth needed to f...
By Kevin Starr • Oct. 23, 2009 -
PharmaVoice Team/PharmaVoice
Table of Contents
on the cover High Stakes: HITECH The pharma industry could come out a winner in the new game of HITECH (Health Information Technology for Economic and Clinical Health Act), if companies can come up with the right ante. FEATURES Publication Planning Update Title VIII of FDAAA, which requires the p...
By PharmaVoice Team • Sept. 30, 2009 -
PharmaVoice Team/PharmaVoice
Christine Bunt: Converging on a Solution
Converging on a Solution Moving from diagnostics to pharmaceuticals, from Europe to the United States, and ultimately from big pharma to a small startup company is not for everybody. But Christine Bunt has the confidence, knowledge, and business acumen to take on any challenge, and she revels in ...
By Kim Ribbink • Sept. 28, 2009 -
PharmaVoice Team/PharmaVoice
Last Word
AstraZeneca’s Dr. Larry Furlong Outlines the Company’s Lean Sigma Program for Process Improvement AstraZeneca is applying the business improvement methodology Lean Sigma to discovery in an attempt to shorten project lead times and increase candidate quality. AstraZeneca’s Larry Furlong, Ph.D., i...
By PharmaVoice Team • Sept. 28, 2009 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical POOL Dr. Per FALK Novo Nordisk Names Clinical Research Head for North America Novo Nordisk, a global healthcare company focusing on diabetes care, has appointed Per Falk, M.D., Ph.D., as VP for clinical, medical, and regulatory affairs for North America. Dr. Falk leads clinical res...
By PharmaVoice Team • Sept. 28, 2009 -
PharmaVoice Team/PharmaVoice
E-Media
New Electronic and Web-based Applications, Sites, and Technologies Featured Briefs: Inclinical, Terrosa Offer Collaborative CTMS Subscription Services Pharsight Offers PK Data Management Solution Compass Healthcare Leverages Social Media in Community Website IMS Health Speeds Access to Promotiona...
By PharmaVoice Team • Sept. 28, 2009 -
PharmaVoice Team/PharmaVoice
What's New
New Healthcare-related Products, Services, and Companies Featured Briefs: FDA Anticounterfeiting Draft Guidance Focuses on Chemical Identifiers inVentiv Renames Professional Development Business PCE Partners with ACU on Continuing Education for NPs, PAs Gullapalli Launches Patient-Centered CME Of...
By PharmaVoice Team • Sept. 28, 2009 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, marketing, And R&D?Trends affecting the healthcare industry Life-Sciences Companies Unprepared for Information Security Risks Despite the promise of the information age and the billions of dollars in economic stimulus funding, many life-sciences and healthcare companies have yet to mee...
By PharmaVoice Team • Sept. 28, 2009 -
PharmaVoice Team/PharmaVoice
The Knowledge Revolution
In 20 to 25 years, pharmaceutical research and development will be multidimensional. Scientists will use artificial intelligence and robotics and interact through a global networked Web. Modeling and simulations that work at different levels, including digital models of “virtual patients," will b...
By PharmaVoice Team • Aug. 24, 2009
Previous
